Clinical trials: Stage II Breast Carcinoma
Breast Cancer
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00796978
- Testing
- trastuzumab, laboratory biomarker analysis, adjuvant therapy
- Where
- 11 sites in United States
- Volunteers
- 56 people
- Sponsor
- Cynthia Owusu, MD
Breast Neoplasms, Breast Cancer
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
The goal of this study is to compare two different types of breast surgery. In the first type, the doctor removes only the tumor.
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Cancer of Breast
- Trial name
- NCT01271738
- Testing
- Remove tumor only, Removal of tumor and tissue
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Emory University
Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer
A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
A phase II study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. Evaluate the effect and safety of irinotecan in local recurrence or Metastatic breast cancer patients who recieved…
- Trial name
- NCT02030678
- Testing
- irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Breast Cancer
Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)
RATIONALE: Estrogen can cause the growth of breast cancer cells. Letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- GIM4 (NCT01064635)
- Testing
- Letrozole
- Where
- Italy
- Volunteers
- 2,056 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Cancer Survivor, Central Obesity
Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors
This randomized phase II trial studies how well physical activity works in reducing metabolic dysregulation in obese Latina breast cancer survivors.
- Conditions
- Cancer Survivor, Central Obesity, No Evidence of Disease
- Trial name
- NCT03120390
- Testing
- Best Practice, Exercise Intervention, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- University of Southern California
Metastatic Breast Cancer
Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer
Abraxane in patients with visceral metastases dominant metastatic breast cancer
- Trial name
- NCT02687490
- Testing
- Abraxane
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Fudan University
Tumors
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
The purpose of this trial is to assess the tolerability and safety of NB1011 in the treatment of patients with cancers that overexpress TS, such as ovarian, gastrointestinal, colorectal, bladder, breast, and lung cancers.
- Trial name
- NCT00248404
- Testing
- NB1011
- Where
- 3 sites in United States, Canada
- Volunteers
- 155 people
- Sponsor
- Kiadis Pharma
Brain Metastases
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
- Trial name
- NCT00538343
- Testing
- berubicin hydrochloride (RTA 744)
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Biogen
Metastatic HER2-Positive Breast Cancer
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
The purpose of this study is to see if a combination of drugs can help to treat breast cancer. This is a Phase II study which will test whether this combination of drugs is effective and will provide further information on side…
- Trial name
- NCT02252887
- Testing
- Gemcitabine, Trastuzumab, Pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Neoplasms
Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients
To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin®)
- Trial name
- NCT00174343
- Testing
- exemestane (Aromasin®)
- Where
- 5 sites in France
- Volunteers
- 46 people
- Sponsor
- Pfizer
Metastatic Breast Cancer, ER+ Breast Cancer
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Analysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy.
- Conditions
- Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- FAIM (NCT04920708)
- Testing
- Ipatasertib 300mg, Fulvestrant 500g, Palbociclib 75mg-125mg
- Where
- 13 sites in United Kingdom
- Volunteers
- 57 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00895414
- Testing
- doxorubicin hydrochloride, enalapril maleate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metastatic Triple Negative Breast Cancer
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib [AZD6738]) and…
- Trial name
- NCT03330847
- Testing
- Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Where
- 141 sites in United States, Belgium and 13 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Breast Cancer
Paclitaxel, Doxorubicin, and Cyclophosphamide With Or Without Carboplatin in Treating Women With Locally Advanced Breast Cancer That Can Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, doxorubicin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00589238
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 2 sites in Singapore
- Volunteers
- 16 people
- Sponsor
- National Cancer Centre, Singapore
Breast Cancer
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer
Immune checkpoint inhibitors given in monotherapy in advanced breast cancer have shown modest benefit in first-line, but very limited efficacy in later lines. Thus, combination therapies are needed.
- Trial name
- ATREZZO (NCT04759248)
- Testing
- Atezolizumab + Trastuzumab + Vinorelbine
- Where
- 15 sites in Spain
- Volunteers
- 55 people
- Sponsor
- SOLTI Breast Cancer Research Group
Breast Cancer
De-Escalation of Axillary Management in Advanced Nodal Disease
This is a prospective, phase 2, single arm trial to evaluate whether Axillary Lymph Node Dissection (ALND) can be safely omitted for patients with cN2 and cN3 breast cancer who achieve a complete clinical response on exam with a…
- Trial name
- DEMAND (NCT07643584)
- Testing
- Axillary Surgery
- Volunteers
- 120 people
- Sponsor
- University of Kansas Medical Center
Breast Cancer, Cancer Survivor
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance
RATIONALE: Studying quality of life in breast cancer survivors may help determine the long-term effects of breast cancer and may help improve the quality of life for future breast cancer survivors.
- Conditions
- Breast Cancer, Cancer Survivor, Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00309933
- Testing
- cognitive assessment, psychosocial assessment and care, quality-of-life assessment
- Where
- 104 sites in United States
- Volunteers
- 2,697 people
- Sponsor
- Eastern Cooperative Oncology Group
Cancer
Safety, Pharmacokinetics (PK) of AKT and MEK Combination
This study is a Phase 1 dose-escalation open-label study to determine the recommended Phase II dose (RP2D) and regimen for the combination of the orally administered MEK inhibitor GSK1120212 and the orally administered AKT kinase…
- Trial name
- NCT01138085
- Testing
- GSK1120212, GSK2141795
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Strength and Range of Motion in Women Undergoing Surgery for Breast Cancer
RATIONALE: Gathering information about strength and range of motion over time from women undergoing surgery for breast cancer may help doctors learn more about recovery from surgery and on-going care.
- Trial name
- NCT00489125
- Testing
- physiologic testing
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery kill any remaining tumor cells and may be an effective treatment for breast cancer.
- Trial name
- NCT01082211
- Testing
- 3D-Conformal External Beam
- Where
- 58 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Radiation Therapy Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.